Global Markets for Asthma and COPD Drugs

  • Print Article |
  • Send to a Friend |
  • |
  • Add to Google |

Markets for Asthma and COPD Drugs

The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%.
Combination asthma/COPD drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%.
The segment made up of asthma drugs is projected to increase from $15.3 billion in 2012 to $20.2 billion in 2017, a CAGR of 5.7%.
COPD drugs are expected to increase from $5.3 billion in 2012 to $5.6 billion in 2017, a CAGR of 1.2%.



This study is intended to provide readers with an understanding of the global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. The study outlines the industry structure, competitive aspects, current developments, and future trends in the market, to assist in identifying areas of commercial interest and potential in the asthma and COPD indications. Drugs Market

The objectives of the study include the assessment of current market status, the analysis of marketed drugs, market revenues, company shares, unmet market needs, market challenges, and future trends. Future market revenues are forecast for the global market, major drug classes, individual disease indication, and largest geographical regions. The study also reviews the compounds currently being investigated in clinical studies for the treatment of asthma and COPD.

Asthma and COPD are two diseases experiencing increasing prevalence globally due to a combination of factors, including a globally aging population and increasing pollution levels. COPD is one of the top five causes of disability and death in industrialized countries and the fourth-leading cause of death globally.

The market for asthma and COPD drugs had global revenues in 2010 that exceeded $34 billion annually. These drugs enjoy tremendous commercial success, as illustrated by the presence of six currently marketed multibillion-dollar drugs in this market. However, there is a perceived high level of unmet need in this market in terms of treatment options for asthma and COPD patients.

With the loss of patent protection on several major COPD and asthma drugs between 2010 and 2017, the cost for some treatments is expected to decrease as generic versions gain market share. Additionally, several new drugs are projected to enter the market through 2017, and they will continue to drive growth of revenues for asthma and COPD drugs.

The report provides a current market overview and projects future developments in the asthma and COPD drugs market over the period from 2011 through 2017. The report describes existing drug classes approved for these indications, such as bronchodilators, anti-inflammatory drugs, and combination drugs of inhaled corticosteroids and bronchodilators. The pipeline of drugs in clinical trials for these indications is also presented and analyzed.

The report includes the following major sections:
Disease overview.
Industry structure and competitive analysis including tiers of competition; regulatory aspects; competitive factors; and market needs, challenges, and trends
Overall market revenue forecast and current market shares as well as revenue forecast by major drug classes, disease indication, and geographical regions.
In-depth analyses of current drug classes.
Reviews and analyses of compounds in clinical trials, with an emphasis on drugs in advanced stages of development.

The report will also analyze product sales and demographics in three regional markets: The Americas (U.S., Canada, Latin/South America); Europe, Middle East, Russia, Africa (EMRA); and Asia (Japan, Australia/New Zealand, other Asian nations, including India and China).

Both primary and secondary research methodologies were used in preparing this study. The analyses and data presented in this report are based on information collected from a variety of industry sources, including pharmaceutical manufacturers and end users. Secondary information sources include company financials and documentation, U.S. Securities and Exchange Commission (SEC) filings, the U.S. Patent and Trademark Office (USPTO), MEDCO Health, World Health Organization (WHO), trade organizations and their publications, online databases, and the medical and scientific literature.

The base year for analysis and forecast is 2011. Revenue forecasts are provided for the period 2012 to 2017. The forecasts are based on a comprehensive analysis of a variety of market and product-specific factors, including historical, current, and future trends; existing and undiagnosed patient populations; unmet market needs; existing product patent expiration dates; the impact of the generic market; and new market entrants and their value proposition and differentiation.

For more information kindly visit :

Article Rating (1 stars):
  • article full star
  • article no star
  • article no star
  • article no star
  • article no star
Rate this Article:
  • Article Word Count: 744
  • |
  • Total Views: 17
  • |
  • permalink
  • Print Article |
  • Send to a Friend |
  • |
  • Add to Google |